{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:11:22Z","timestamp":1790871082074,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["454363"],"award-info":[{"award-number":["454363"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["251608"],"award-info":[{"award-number":["251608"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["454569"],"award-info":[{"award-number":["454569"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fiona Elsey Cancer Research Institute"},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The causes of multiple myeloma (MM) remain obscure and there are few known risk factors; however, natural killer T (NKT) cell abnormalities have been reported in patients with MM, and therapeutic targeting of NKT cells is promoted as a potential treatment. We characterized NKT cell defects in treated and untreated patients with MM and determined the impact of lenalidomide therapy on the NKT cell pool. Lenalidomide is an immunomodulatory drug with co-stimulatory effects on NKT cells in vitro and is an approved treatment for MM, although its mode of action in that context is not well defined. We find that patients with relapsed\/progressive MM had a marked deficiency in NKT cell numbers. In contrast, newly diagnosed patients had relatively normal NKT cell frequency and function prior to treatment, although a specific NKT cell deficiency emerged after high-dose melphalan and autologous stem cell transplantation (ASCT) regimen. This also impacted NK cells and conventional T cells, but the recovery of NKT cells was considerably delayed, resulting in a prolonged, treatment-induced NKT cell deficit. Longitudinal analysis of individual patients revealed that lenalidomide therapy had no in-vivo impact on NKT cell numbers or cytokine production, either as induction therapy, or as maintenance therapy following ASCT, indicating that its clinical benefits in this setting are independent of NKT cell modulation.<\/jats:p>","DOI":"10.1111\/cei.12196","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T08:12:28Z","timestamp":1377763948000},"page":"49-58","source":"Crossref","is-referenced-by-count":43,"title":["Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy"],"prefix":"10.1093","volume":"175","author":[{"given":"A C","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Neeson","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia"},{"name":"Division of Research, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Leeansyah","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tainton","sequence":"additional","affiliation":[{"name":"Division of Research, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Quach","sequence":"additional","affiliation":[{"name":"Division of Research, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia"},{"name":"Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Prince","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia"},{"name":"Division of Research, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia"},{"name":"Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Harrison","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia"},{"name":"Division of Research, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia"},{"name":"Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D I","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia"},{"name":"Division of Research, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia"},{"name":"Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S P","family":"Berzins","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic., Australia"},{"name":"University of Ballarat, Ballarat, Vic., Australia"},{"name":"Fiona Elsey Cancer Research Institute, Ballarat, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"key":"2021122010004731900_cei12196-bib-0001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2021122010004731900_cei12196-bib-0002","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"2021122010004731900_cei12196-bib-0003","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI200423594","article-title":"Going both ways: immune regulation via CD1d-dependent NKT cells","volume":"114","author":"Godfrey","year":"2004","journal-title":"J Clin Invest"},{"key":"2021122010004731900_cei12196-bib-0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","article-title":"Presumed guilty: natural killer T cell defects and human disease","volume":"11","author":"Berzins","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2021122010004731900_cei12196-bib-0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/156652409787314534","article-title":"Natural killer T cells and autoimmune disease","volume":"9","author":"Wu","year":"2009","journal-title":"Curr Mol Med"},{"key":"2021122010004731900_cei12196-bib-0006","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/clim.2001.5060","article-title":"Circulating V alpha 24(+) V beta 11(+) NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage","volume":"100","author":"van der Vliet","year":"2001","journal-title":"Clin Immunol"},{"key":"2021122010004731900_cei12196-bib-0007","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.coi.2010.10.008","article-title":"Role of NKT cells in allergic asthma","volume":"22","author":"Iwamura","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"2021122010004731900_cei12196-bib-0008","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"2021122010004731900_cei12196-bib-0009","first-page":"293","article-title":"CD1-restricted T cells and tumor immunity","volume":"314","author":"Swann","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"2021122010004731900_cei12196-bib-0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-230X(08)00408-9","article-title":"The role of NKT cells in tumor immunity","volume":"101","author":"Terabe","year":"2008","journal-title":"Adv Cancer Res"},{"key":"2021122010004731900_cei12196-bib-0011","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/jid.2009.30","article-title":"Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions","volume":"129","author":"Balato","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2021122010004731900_cei12196-bib-0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1749-6632.2009.04931.x","article-title":"Harnessing CD1d-restricted T cells toward antitumor immunity in humans","volume":"1174","author":"Neparidze","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"2021122010004731900_cei12196-bib-0013","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2010.12.010","article-title":"Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges","volume":"140","author":"Dhodapkar","year":"2011","journal-title":"Clin Immunol"},{"key":"2021122010004731900_cei12196-bib-0014","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2021122010004731900_cei12196-bib-0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.beha.2007.10.002","article-title":"Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation","volume":"20","author":"Rajkumar","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122010004731900_cei12196-bib-0016","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s13277-013-0743-x","article-title":"The role of natural killer T cells in B cell malignancies","volume":"34","author":"Ghalamfarsa","year":"2013","journal-title":"Tumour Biol"},{"key":"2021122010004731900_cei12196-bib-0017","doi-asserted-by":"crossref","first-page":"e65075","DOI":"10.1371\/journal.pone.0065075","article-title":"Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model","volume":"8","author":"Nur","year":"2013","journal-title":"PLOS One"},{"key":"2021122010004731900_cei12196-bib-0018","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0019","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1158\/1078-0432.CCR-07-5290","article-title":"Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy","volume":"14","author":"Song","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122010004731900_cei12196-bib-0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","article-title":"Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma","volume":"121","author":"Richter","year":"2013","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0021","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0022","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2008-04-149831","article-title":"Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer","volume":"112","author":"Chang","year":"2008","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0023","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2012-11-465849","article-title":"Can NKT cells extinguish smoldering myeloma?","volume":"121","author":"Benson","year":"2013","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0024","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"Gorgun","year":"2010","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0025","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2165\/00003495-200767130-00005","article-title":"Lenalidomide in myelodysplastic syndrome and multiple myeloma","volume":"67","author":"Shah","year":"2007","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"2021122010004731900_cei12196-bib-0026","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cco.0000410243.84074.dc","article-title":"Review of therapy for relapsed\/refractory multiple myeloma: focus on lenalidomide","volume":"24","author":"Mariz","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2021122010004731900_cei12196-bib-0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"2021122010004731900_cei12196-bib-0029","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/leu.2009.279","article-title":"Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients","volume":"24","author":"Chan","year":"2010","journal-title":"Leukemia"},{"key":"2021122010004731900_cei12196-bib-0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/187221310791163026","article-title":"Pharmacological properties of thalidomide and its analogues","volume":"4","author":"De Sanctis","year":"2010","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"2021122010004731900_cei12196-bib-0031","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"2021122010004731900_cei12196-bib-0032","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J Exp Med"},{"key":"2021122010004731900_cei12196-bib-0033","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20011908","article-title":"Distinct functional lineages of human V(alpha)24 natural killer T cells","volume":"195","author":"Lee","year":"2002","journal-title":"J Exp Med"},{"key":"2021122010004731900_cei12196-bib-0034","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20011786","article-title":"Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining","volume":"195","author":"Gumperz","year":"2002","journal-title":"J Exp Med"},{"key":"2021122010004731900_cei12196-bib-0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.it.2007.05.008","article-title":"NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis","volume":"28","author":"Terabe","year":"2007","journal-title":"Trends Immunol"},{"key":"2021122010004731900_cei12196-bib-0036","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20050953","article-title":"Differential antitumor immunity mediated by NKT cell subsets in vivo","volume":"202","author":"Crowe","year":"2005","journal-title":"J Exp Med"},{"key":"2021122010004731900_cei12196-bib-0037","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cei.12045","article-title":"Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(\u2013) subsets","volume":"172","author":"Chan","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2021122010004731900_cei12196-bib-0038","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"2021122010004731900_cei12196-bib-0039","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri2451","article-title":"Harnessing invariant NKT cells in vaccination strategies","volume":"9","author":"Cerundolo","year":"2009","journal-title":"Nat Rev Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/1\/49\/41789153\/cei12196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/1\/49\/41789153\/cei12196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:25:17Z","timestamp":1641036317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/175\/1\/49\/6421176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,12,3]]},"published-print":{"date-parts":[[2013,12,3]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12196","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,1]]},"published":{"date-parts":[[2013,12,3]]}}}